Related Experiment Video

Updated: Jan 22, 2026

Monitoring Breast Cancer Growth and Metastatic Colony Formation in Mice using Bioluminescence
06:52

Monitoring Breast Cancer Growth and Metastatic Colony Formation in Mice using Bioluminescence

Published on: November 5, 2021

3.6K

Olaparib in germline-mutated metastatic breast cancer: implications of the OlympiAD trial

Anne C Armstrong1, Vanessa Clay1

  • 1Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road Manchester, M20 4BX, UK.

Future Oncology (London, England)
|July 16, 2019
PubMed

Insights

Olaparib significantly improved progression-free survival in patients with HER2-negative metastatic breast cancer and BRCA mutations. This PARP inhibitor offers a new therapeutic option for this specific breast cancer subtype.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Breast cancer is a major global health concern.
  • Advances in understanding cancer cell mechanisms enable new therapeutic targets.
  • Poly(ADP-ribose) polymerase (PARP) is crucial for DNA repair, making it a target for cancer therapy.

Purpose of the Study:

  • To review the findings of the Phase III OlympiAD trial.
  • To evaluate the efficacy of the PARP inhibitor Olaparib in specific breast cancer patients.
  • To discuss the implications of Olaparib in treating BRCA-mutated breast cancer.

Main Methods:

  • Phase III clinical trial design.
  • Evaluation of Olaparib in patients with HER2-negative metastatic breast cancer.
  • Focus on patients with germline BRCA-mutations and defective DNA repair pathways.

Main Results:

  • Olaparib demonstrated a significant progression-free survival advantage.
  • The trial specifically assessed outcomes in HER2-negative metastatic breast cancer patients.
  • A notable benefit was observed in individuals with a germline BRCA-mutation.

Conclusions:

  • Olaparib represents a promising therapeutic strategy for BRCA-mutated breast cancer.
  • The OlympiAD trial results support the use of PARP inhibitors in this patient population.
  • Further implications for targeted therapy in metastatic breast cancer are suggested.
Keywords:
OlympiADbreast cancerolaparib

More Related Videos

Generating a Murine Orthotopic Metastatic Breast Cancer Model and Performing Murine Radical Mastectomy05:05

Generating a Murine Orthotopic Metastatic Breast Cancer Model and Performing Murine Radical Mastectomy

Published on: November 29, 2018

11.6K
Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer07:13

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

Published on: March 26, 2014

23.9K

Related Concept Videos

Mutations01:39

Mutations

Overview
94.4K
Mutations01:35

Mutations

Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
44.0K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.6K
Viral Mutations00:36

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
39.8K
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.2K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K